After a rocky early launch, Iovance now has a cancer treatment already cleared for use, and the story shifts from “will it work?” to “can it catch on” as more hospitals come on board and manufacturing improves. If results in other hard-to-treat cancers hold up, the company could grow far beyond melanoma—and it may even draw interest from a bigger drugmaker looking to fill future gaps.Read more
Key Takeaways Expanded distribution and positive clinical data are set to boost adoption of Amtagvi and strengthen revenue growth in oncology markets. Operational streamlining, new pipeline advancements, and global expansion efforts are expected to improve profitability and diversify long-term earnings.Read more
A cancer therapy company could see a quicker ramp than many expect if doctors keep adopting its newest treatment and more hospitals can offer it. But the story hinges on scaling complex manufacturing and avoiding setbacks from regulators, insurers, and fast-moving rivals.Read more
Key Takeaways Sustained high costs, complex distribution, and slow commercialization delay profitability and threaten market share amid rising competition from newer cancer therapies. Ongoing financial challenges, including exposure to interest rates and revenue pressure from drug pricing scrutiny, heighten risk of shareholder dilution and reduced margins.Read more
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
